232
Views
1
CrossRef citations to date
0
Altmetric
Research Articles

Insilico drug designing for COVID-19: an approach of high-throughput virtual screening, molecular, and essential dynamics simulations

ORCID Icon, ORCID Icon & ORCID Icon
Pages 7394-7407 | Received 03 Aug 2020, Accepted 25 Feb 2021, Published online: 10 Mar 2021
 

Abstract

Severe acute respiratory syndrome-coronavirus2 (SARS-CoV2), a new coronavirus has emerged in Wuhan city of China, December 2019 causing pneumonia named Coronavirus disease-19 (COVID-19), which has spread to the entire world. By January 2021, number of confirmed cumulative cases crossed ∼104 million worldwide. Till date, no effective treatment or drug is available for this virus. Availability of X-ray structures of SARS-CoV2 main protease (Mpro) provides the potential opportunity for structure-based drug designing. Here, we have made an attempt to do computational drug design by targeting main protease of SARS-CoV2. High-throughput virtual screening of million molecules and natural compounds databases were performed followed by docking. After that, the protein-ligand complexes were optimized and rescoring of binding energies were accomplished through molecular dynamics simulation and Molecular mechanics Poisson Boltzmann surface area approaches, respectively. In addition, conformational effect of various ligands on protein was also examined through essential dynamics simulation. Three compounds namely ZINC14732869, ZINC19774413, and ZINC19774479 were finally filtered that displayed better binding affinities than N3 (known) inhibitor and formed conformationally stable complexes. Hence, the current study features the potential novel inhibitors against main protease of SARS-CoV2 which might provide an effective therapeutic strategy against COVID-19.

Communicated by Ramaswamy H. Sarma

Disclosure statement

No potential conflict of interest is reported by the authors.

Authors’ contributions

Rakesh K. and Pranay T. conceived and designed the study. Rakesh K. and Rahul K. performed experiments, analyzed the data and wrote manuscript. P.T. provided laboratory infrastructure. All authors read and approved the final version of manuscript.

Additional information

Funding

Rakesh and Rahul thank Indian Council of Medical Research and University Grant Commission, respectively, for financial support.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.